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Abstract
A decrease in functional beta-cell mass is a key feature of type 2 diabetes. Glucagon-like peptide 1 (GLP-1) analogues induce
proliferation of rodent beta-cells. However, the proliferative capacity of human beta-cells and its modulation by GLP-1
analogues remain to be fully investigated. We therefore sought to quantify adult human beta-cell proliferation in vitro and
whether this is affected by the GLP-1 analogue liraglutide. Human islets from 7 adult cadaveric organ donors were
dispersed into single cells. Beta-cells were purified by FACS. Non-sorted cells and the beta-cell enriched (‘‘beta-cells’’)
population were plated on extracellular matrix from rat (804G) and human bladder carcinoma cells (HTB9) or bovine corneal
endothelial ECM (BCEC). Cells were maintained in culture+/2liraglutide for 4 days in the presence of BrdU. Rare human
beta-cell proliferation could be observed either in the purified beta-cell population (0.05160.020%; 22 beta-cells
proliferating out of 84’283 beta-cells counted) or in the non-sorted cell population (0.05560.011%; 104 proliferating beta-
cells out of 232’826 beta-cells counted), independently of the matrix or the culture conditions. Liraglutide increased human
beta-cell proliferation on BCEC in the non-sorted cell population (0.08260.034% proliferating beta-cells vs. 0.01760.008% in
control, p,0.05). These results indicate that adult human beta-cell proliferation can occur in vitro but remains an extremely
rare event with these donors and particular culture conditions. Liraglutide increases beta-cell proliferation only in the non-
sorted cell population and only on BCEC. However, it cannot be excluded that human beta-cells may proliferate to a greater
extent in situ in response to natural stimuli.
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Introduction
Type 2 diabetes is characterized by a progressive decrease in
functional beta-cell mass that can no longer compensate for insulin
resistance [1,2]. In this context, the ability of murine and rodent
beta-cells to proliferate as one possible route to compensate for the
decrease in beta-cell mass has been extensively studied [3].
However, whether adult human beta-cells are able to proliferate
remains under debate [4–7]. A low rate of human beta-cell
proliferation has been observed in vivo [8–10] in pancreatic
sections. In vitro, some studies failed to detect any adult human
beta-cell proliferation [4], whereas others observed proliferation at
a rate .1% [6]. The ability of beta-cells to proliferate in vitro
varies depending on their contact to different extracellular
matrices [4,11,12] which might explain some of the discrepancies
between studies from various research groups.
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1)
derivative that has been shown to preserve beta-cell mass by
inducing proliferation of rat and mouse beta-cells [4,8]. However,
the proliferative capacity of human beta-cells and its modulation
by GLP-1 analogues remains to be fully investigated.
The aim of this study was to determine whether human beta-
cells are able to proliferate in vitro under different culture
conditions and whether this may be modulated by the GLP-1
analogue liraglutide. To answer these questions, sorted human
beta-cells and human non-sorted islet cells were cultured on 3
different matrices, each with 4 different treatment conditions and
in the continuous presence of BrdU. These experiments were
conducted by two independent research groups under the same
conditions regarding the timeline of the experiments, the origin of
the matrices and the reagents used as well as the method with
which the cells were counted.
Methods
Human islet isolation and culture
Human islets were isolated from pancreata of organ donors at
the University of Geneva Medical Centre (Switzerland) and at the
University of Milan (Italy) (n = 7; Age average: 49.3 years; (range
18–66); BMI average: 26.5 (range 21.6–36.9)). Human islets were
provided by the islet for research distribution program through the
European Consortium for Islet Transplantation, under the
supervision of the Juvenile Diabetes Research Foundation (31-
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35801
2008-416) Islets were obtained in Milano with patient consent
governed by the laws of the Nord Italia Transplant Program, with
ethical approval from the Comitato Etico Istituto Scientifico San
Raffaele. Islets were obtained in Geneva with ethical approval
from the N.A.C. (Neuclid, Apsic (Anesthesiology, Pharmacology,
Surgery intensive care), Surgery) Joint Departmental Ethical
Committee of the University Hospital and according to Swiss
legislation on cadaveric tissue procurement. Human islets used in
this study were analyzed anonymously. Human islets were
cultured in CMRL-1066 medium containing 5 mmol/l glucose,
100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM gluta-
max, 250 mg/ml gentamycine, 10 mM Hepes and 10% FCS
(Invitrogen, Basel, Switzerland). The islets were cultured overnight
in suspension dishes at a concentration of 500 islets equivalent/ml
and collected by centrifugation; the supernatant was kept as
‘conditioned medium’ at 4uC. To obtain single cells, islets were
dispersed with Accutase (PAA Laboratories, Pasching, Austria) for
10 minutes at 37uC. Beta-cells were purified using a FACSVan-
tage (Becton Dickinson, Sunnyvale, CA, USA) as described [4] by
virtue of their zinc content using the zinc-binding fluorochrome
Newport Green. Non-sorted single cells and sorted beta-cells were
cultured on extracellular matrix-coated plates derived from bovine
corneal endothelial cells (BCEC, Novamed, Jerusalem, Israel),
804G or HTB9 as described elsewhere [4] and were left in islet
media for 24 h to adhere and spread before initiation of the
experiments. Cells were treated with Liraglutide (100 nM, kindly
provided by Novo Nordisk, Denmark) and/or conditioned media.
Medium was changed after 2 days of culture (Fig. 1).
Proliferation of islet cells
BrdU was added to the cells at the start of the treatment. After 4
days treatment, the incorporated BrdU was detected with an anti-
BrdU antibody (dilution 1/10, incubation 30 minutes at 37uC,
Roche, Basel, Switzerland). The single cells were co-stained with a
guinea pig anti-insulin antibody (Dako, Glostrup, Denmark,
Dilution 1/50, 30 minutes at 37uC) and DAPI to stain all nuclei.
For each condition in each individual experiment, the total cell
number, insulin-positive cells, BrdU-positive cells and double
positive insulin/BrdU cells (considered as proliferating beta-cells)
present on each dish were counted blindly with Image J (NIH,
Bethesda, Maryland, USA) and Adobe Photoshop CS4 (Adobe
Systems, San Jose, California, USA) on pictures taken with
fluorescent microscopes (AxioZ1, Zeiss, Jena, or Olympus BX61,
Hamburg, Germany), in parallel by 2 different investigators in
Geneva and Basel. Each n represents a different human islet
donor.
Statistical analysis
Data are expressed as means 6 SEM. All data were tested for
normality and analyzed with PRISM (GraphPad, San Diego, CA).
Significance was tested using Student’s t test and Mann-Whitney
for multiple comparison analysis. Significance was set as P,0.05.
Results
Non-sorted dispersed human islet cells and sorted human beta-
cells were cultured on 3 different extracellular matrix-coated
Figure 1. Overview and timeline of the experiments. Overview (a) and timeline (b) of the experiments showing the different cell fractions,
matrices and treatments evaluated. CM, conditioned medium; Lira, Liraglutide; BCEC, bovine corneal endothelial cell; 804G, rat bladder carcinoma;
HTB9 human bladder carcinoma.
doi:10.1371/journal.pone.0035801.g001
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dishes in the presence of BrdU and treated with Liraglutide and/
or conditioned medium. After 4 days of treatment, cells were co-
immunostained for BrdU incorporation and insulin. The number
of total cells present on the dishes at the end of the experiment was
not changed by the matrices or any of the treatments as
determined by DAPI staining. Similarly, the percentage of
proliferating insulin-negative cells observed on dishes containing
non-sorted cells (0.16460.029%) was independent of matrices and
treatments. In the sorted beta-cell fraction, a purity of
98.6360.19% was obtained at the end of the culture period,
and this too was unaffected by the different matrices or treatments.
Proliferation of sorted beta-cells is not influenced by
matrix or treatment
Neither Liraglutide nor conditioned medium nor the combina-
tion of the 2 treatments had any effect on the percentage of BrdU/
insulin-double positive cells (data not shown). There were also no
significant differences in beta-cell proliferation among the 3
different matrices (Table 1). This allowed for the data from all
conditions to be pooled, with a total of 22 proliferating beta-cells
out of 84,283 beta-cells scored in 7 independent experiments,
resulting in an overall rate of 0.05160.020% (Table 1).
Liraglutide induces beta-cell proliferation only in non-
sorted cells on BCEC
The non-sorted single cells contained 52.3762.03% beta-cells,
which was not changed by any of the various conditions. We
observed a total of 104 proliferating beta-cells out of 232’826 beta-
cells or 0.05560.011%, similar to that found in sorted beta-cells
(Table 1, last row). Liraglutide alone increased BrdU incorpora-
tion only in cells cultured on BCEC (0.01760.008 vs 0.08260.034
control vs Liraglutide, p,0.05). On this matrix, cells from 6 out of
7 donors showed an increase in beta-cell proliferation in response
to Liraglutide. There was no significant difference among any of
the other conditions (treatment or matrices).
Taken together, we observed rare in vitro proliferating human
beta-cells in sorted cells as well as in dispersed islets. The rate of
proliferation was unchanged by different treatment and matrices.
Liraglutide increased beta-cell proliferation only in non-sorted
cells and only on BCEC.
Discussion
In this study we found that adult human beta-cells proliferate in
vitro. However, this remains an extremely rare event. We used
BrdU incorporation which allowed us to detect the proliferation
that had arisen over 4 days, whereas the other staining methods for
proliferation only detect the cells replicating at the time of fixation.
Given the rarity of this event and despite the very large numbers of
cells observed, the use of any other staining method than BrdU
would likely have precluded our ability to quantify proliferation.
However, BrdU does not discriminate between proliferating cells
and incorporation due to repair following DNA damage,
indicating that our data regarding human beta-cell proliferation
may if anything be an over-estimate.
Our results are in line with results from others [5–7] but clearly
diverge from our earlier study [4]. In these experiments,
proliferating human beta-cells could not be detected at all, also
not in the presence of different growth factors and hormones
including Liraglutide. This discrepancy may be explained by the
rarity of the event in combination with a different microscopy and
counting method, as well as the smaller number of cells examined
for each donor.
The proliferation observed in our study was not influenced by
islet conditioned medium or the presence of other islet cells. Our
data thus showed that purified human beta-cells (purity .98%)
are able to proliferate in vitro to the same extent as beta-cells
surrounded by the various other islet cell types. Our results did not
tell us the origin of the proliferating beta-cells. However the similar
proliferation rate between beta-cells in the sorted and in the non-
sorted fractions suggests that self-replication or dedifferentiation-
proliferation-redifferentiation could be more probable routes for
proliferation than neogenesis from precursor cells or transdiffer-
entiation.
These data with rare proliferative adult human beta-cells do not
allow us to draw any conclusions regarding beta-cell proliferation
in vivo in adult humans, and the potential beneficial effect of GLP-
1-based therapy in such a context. Moreover, it cannot be
excluded that human beta-cells may proliferate to a greater extent
in situ in response to natural physical and humoral stimuli within
the physiological setting of the islet. In this series of 7 donors, the
majority were above 50 years old, only 2 donors were younger (18
and 38 respectively). This series did not allow us to observe any
correlation or trend between proliferation and age. Previous
Table 1. Beta-cell proliferation and number of total cells evaluated in sorted human beta-cells and non-sorted dispersed islet cells
cultured on 3 different matrices in control medium or with Liraglutide and/or conditioned medium (n = 7).
Sorted beta-cells Non-sorted cells
Pooled treatmentsa Control Lira CM CM+Lira
% BrdU+/Ins+ BCEC 0.03460.019 0.01760.008 0.08260.034 * 0.04260.014 0.02760.014
804 G 0.01560.004 0.03260.026 0.01160.005 0.04960.029 0.18660.088
HTB9 0.09760.082 0.02860.025 0.04760.034 0.09760.040 0.03560.024
Sorted beta-cells Non-sorted cells
Number of cells counted Total cells 85’412 525’001
Beta cells 84’283 232’826
BrdU+/Ins+ 22 104
% BrdU+/Ins+ Pooled matrices and treatments 0.05160.020 0.05560.011
aFor each matrix, the numbers of proliferating beta-cells were pooled from dishes treated with control media 6Liraglutide or condit.media 6 Liraglutide.
*represents p,0.05 as tested by Mann-Whitney.
CM, conditioned medium; Lira, Liraglutide; BCEC, bovine corneal endothelial cell; 804 G, rat bladder carcinoma; HTB9, human bladder carcinoma.
doi:10.1371/journal.pone.0035801.t001
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studies have shown a decrease in adult human beta-cell
proliferation with age ([6,8–10]. These correlations have been
observed on pancreatic sections where tissues from very young
(,10 years) or very old (.80 years) patients were included; these
are age groups from which isolated islets are typically not
available. Our study also differs in methodology from a previous
study [6] where age-dependent effects have been observed on
cultures of whole islets.
In the present study, the baseline proliferation of adult human
beta-cells was comparable among the 3 different matrices used.
These extracellular matrices may not offer the optimum
substratum for human beta-cell proliferation and are in any case
not similar in composition or structure to the naturally occurring
basement membrane surrounding human beta-cells [4,11,13].
Interestingly, Liraglutide increased proliferation of adult human
beta-cells only in the non-sorted cell fraction cultured on
BCEC.However, even in the presence of this GLP-1 analogue
and BrdU throughout the 4 day culture period, ,0.1% of beta-
cells were seen to have proliferated. The results obtained here with
human adult beta-cells differ clearly from those obtained
previously with rat or mouse beta-cells [4,14]. There, replication
is considered to be the main mechanisms for the maintenance of
beta-cell mass with rates of proliferation predicted to reach .20%
under these same conditions in response to GLP-1. There thus is a
striking difference between rodent and adult human beta-cells in
their capability to proliferate. This raises the question of the
relevance of mouse or rat beta-cells as a model for studying the
impact of pharmacological compounds on human beta-cell
proliferation.
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